Updated: Oct 19
Medically reviewed by ChinaCureLink Team
Table of Content
Why This Case Matters
This case follows Mr. Huang (alias), a 56-year-old liver cancer patient whose disease had spread across six segments of his liver — too diffuse for surgery — and who achieved tumor suppression through a staged, two-part yttrium-90 (Y90) treatment combined with systemic therapy at a licensed oncology hospital in Guangzhou. For international patients with multifocal or bilobar liver cancer that isn't a candidate for surgical resection, ChinaCureLink can help evaluate access to this same combined treatment approach.
Key Takeaways |
|
Patient Background
Mr. Huang had lived with hepatitis B for 40 years without consistent medical monitoring. In October 2023, a routine checkup found an occupying lesion in his liver; at the time, it was considered possibly benign, and he began oral antiviral and liver-protective treatment. Less than a year later, in August 2024, a re-examination at a Grade A hospital in Guangzhou told a different story: enhanced MRI showed multiple nodules throughout his liver, raising strong suspicion of liver cancer with intrahepatic spread. Seeking further options, he came to a licensed oncology hospital in Guangzhou to learn about Y90 therapy.
The Care Team and Approach
Imaging on August 28, 2024 confirmed multiple nodules across Mr. Huang's liver consistent with malignancy, along with cirrhotic changes. The following day, his care team performed a detailed mapping evaluation — placing microcatheters into his liver's arterial branches and using imaging to trace each tumor's blood supply. That mapping revealed tumors spread across six separate liver segments, on both sides of the liver: disease too extensive and diffuse for surgical removal to be a realistic option.
Given the scale of his disease, the hospital's multidisciplinary team decided on a staged approach rather than a single procedure: treating the tumor burden on the right side of his liver first, then returning three weeks later to treat the left side. On September 4, 2024, Mr. Huang underwent right hepatic super-selective Y90 radioembolization; on September 24, the team completed the left side. Throughout treatment, he continued on a systemic immunotherapy combination (atezolizumab plus bevacizumab) administered every three weeks, working alongside the localized Y90 treatment to address his disease from multiple angles.
Each Y90 procedure followed the same precise process: microcatheters were guided back to the exact positions identified during mapping, a nuclear medicine physician calculated and prepared a precise dose of radioactive resin microspheres for each patient, and the care team confirmed good blood flow with no stasis or reflux before slowly infusing the microspheres into the targeted vessels.
Treatment Timeline/ Process
Before Treatment
40-year history of hepatitis B without regular monitoring
October 2023: Routine checkup found a liver lesion, initially considered possibly benign; began antiviral and liver-protective treatment
August 2024: Re-examination revealed multiple liver nodules, raising suspicion of liver cancer with intrahepatic spread
At the Hospital
August 28, 2024: MRI confirmed multiple malignant-appearing liver nodules and cirrhotic changes
August 29, 2024: Mapping evaluation identified tumors across six liver segments on both sides of the liver
September 4, 2024: Underwent right hepatic Y90 radioembolization
September 24, 2024: Underwent left hepatic Y90 radioembolization
Continued systemic immunotherapy (atezolizumab plus bevacizumab) every three weeks throughout treatment
Discharged five days after treatment, recovering well
Follow-Up
January 10, 2025: PET-CT showed liver lesions had shrunk, with no increased glucose metabolism — indicating suppressed tumor activity; systemic therapy was paused following a comprehensive evaluation
Outcome
Four months after completing his staged Y90 treatment, Mr. Huang's follow-up PET-CT showed his liver lesions had shrunk, with no increased glucose metabolism at the tumor sites — a sign that tumor activity had been suppressed. Based on that result, his care team paused his systemic immunotherapy following a comprehensive evaluation. His case reflects tumor control and suppression rather than a documented complete cure, and continued monitoring remains part of his care.
How ChinaCureLink Can Help International Patients to Access This Treatment
Diffuse or bilobar liver cancer — disease spread across multiple liver segments on both sides — often rules out surgery entirely, but as Mr. Huang's case shows, a staged, multidisciplinary approach combining Y90 radioembolization with systemic therapy can still meaningfully control the disease. ChinaCureLink helps international patients with multifocal or advanced liver cancer get a specialized case review and connects them with hospitals in China experienced in staged Y90 treatment and combined immunotherapy protocols, coordinating medical record translation, hospital matching, and every logistical step from first inquiry through treatment and follow-up.
Get a Second Opinion Before Fly to China
For suitable cases, ChinaCureLink can then coordinate an online consultation with the specialist to discuss the technical treatment details directly. The purpose is to help the patient understand which treatment option and which specialist center may be most appropriate before making an international treatment decision.
What Patients Say About ChinaCureLink & Medebound HEALTH
China CureLink operates under Medebound HEALTH — an internationally recognized healthcare navigation company incorporated in New York, with operations across North America and Asia-Pacific.
Rated 4.6 ⭐⭐⭐⭐⭐ at Trustpilot
Medebound HEALTH's online testimonials. Learn More
★★★★☆ Sarah Zhang · Canada· Jul 2024 · Verified “The interpreter during the video call was fantastic — super professional and answered all our questions clearly and quickly. The professor was also very patient and gave us detailed and honest guidance on our treatment options.” |
★★★★★ Andrew Goh · Singapore · Aug 2024 · Verified “My first contact with Medebound was over a year ago. Jason has always been responsive, even when I wasn't ready to proceed. When I finally did, the consultation was seamlessly arranged and the specialist was outstanding.” |
★★★★★ Daniel Wong · Singapore · Aug 2024 · Verified “I have dry eye and nothing seemed to be working, even with different medications. I heard about a medication from the U.S. that’s supposed to be really effective, but I didn’t want to try it without talking to a doctor first. MEDEBOUND connected me with a top ophthalmologist in the U.S. and it was so reassuring to get their expert advice.” |
★★★★☆ Pongsakorn · Thailand · Feb 2025 · Verified “Kiki at Medebound is amazing — so professional and helpful! They got my video consultation with an MD Anderson expert set up super fast, within just 5 working days. I am so grateful for their support.” |
Frequently Asked Questions
Can Y90 therapy treat liver cancer that has spread to both sides of the liver?
Yes — as this case shows, Y90 treatment can be staged into separate procedures for each side of the liver when disease is too extensive to treat in a single session. A specialist evaluation determines the right sequencing and timing for each case.
Is Y90 therapy combined with other treatments like immunotherapy?
It often is. Combining localized Y90 treatment with systemic therapy, such as immunotherapy, is a common approach for more extensive liver cancer, addressing the disease both locally and throughout the body.
How can international patients access Y90 therapy for liver cancer in China?
Access typically starts with a case review, where imaging, pathology, and treatment history are submitted for evaluation. ChinaCureLink coordinates this process and helps match patients with hospitals experienced in staged and combination Y90 treatment protocols.
About ChinaCureLink
ChinaCureLink helps patients across the world access the best cancer treatment at China's top hospitals, without the delays, language barriers, and administrative confusion that typically come with seeking care abroad.
We connect patients directly with China's top cancer hospitals, ensuring that from the first case submission through to treatment and follow-up, every step is guided, translated, and coordinated by a team experienced in cross-border patient care.
ChinaCureLink is proudly affiliated with Medebound HEALTH — founded by US physicians, with over 10 years of experience and more than 3,000 patients served worldwide, Medebound HEALTH is recognized by Forbes and it is one of the most trusted patient cross-border concierge service company across North America and the Asia Pacific.
Disclaimer
This account reflects one patient's individual experience, which will vary by case, diagnosis stage, and other clinical factors. ChinaCureLink facilitates access to hospitals and treatment coordination — we do not provide medical care ourselves, and this content is not medical advice. Patients and families should consult a qualified hepatologist or interventional oncologist before making treatment decisions.
